// App-Quantinova.ai

: Impact of circulating tumor cell (CTC) nucleus size on outcomes with abiraterone acetate (AA) therapy in men with metastatic castration-resistant prostate cancer (mCRPC).

Researchers

Presenter

  • David Michael Gill

Principal Investigators

  • Neeraj Agarwal

  • Andrew W. Hahn

  • Eric Johnson

  • Austin Poole

  • Emma Carroll

  • Kenneth M. Boucher

  • Mohamed E. Salama

  • Archana M. Agarwal

Medical Centers

  • Huntsman Cancer Institute at the University of Utah, Salt Lake City, UT

  • Huntsman Cancer Institute-University of Utah Health Care, Salt Lake City, UT

  • Huntsman Cancer Institute at the University of Utah, Salt Lake City, UT

  • Department of Pathology and ARUP Laboratories, University of Utah, Salt Lake City, UT

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Nephrology

Disease

  • N/A

Biomarkers

  • Circulating tumor cells

  • Prostate specific antigen

Drug/Treatment

  • CB-7598

Outcome

  • N/A

Study Design

  • Cohort

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved